The Role of Nueroinflammation in Rosacea

November 1, 2016

Rosacea is one of the most common chronic inflammatory skin diseases, and although it is frequently diagnosed, its pathophysiology is still poorly understood. Continued research has shed some light on the pathophysiology of rosacea and has brought neuroinflammation and neurogenic inflammation to the forefront as an important factor in the development of the disease. The hope is that therapies possibly targeting these pathways could prove effective, offering a beacon of hope for this often challenging to treat skin disease.
Recognized as a complex disease, rosacea can be characterized by a mosaic of symptoms including facial erythema (sometimes burning and painful) and telangiectasias, papules and pustules, as well as facial edema, typically occurring first on the central face around the nose, cheeks, forehead, and chin.
According to the presentation of symptoms, rosacea can be further divided into four subgroups, namely, erythematotelangiectatic rosacea (erythema, flushing, telangiectasias), papulopustular rosacea (erythema, edema, acne-like lesions), phymatous rosacea (rhinophymatous changes), and ocular rosacea (red, itchy, irritated eyes, swollen eyelids).

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • FDA Advisory Committee Recommends Adding Six of Seven Peptides to Compounding List
    • FDA Advisory Committee Recommends Adding BPC-157 to Compounding List
    • FDA to Review Peptides: What Med Spa Professionals Should Know Ahead of the July 23–24 Meeting
    • Merz Aesthetics Reintroduces Neocutis Journée Revitalizing Day Cream SPF 30
    • Allergan Receives Approval for Boey (trenibotulinumtoxinE) in Europe